Iterum TherapeuticsITRMF +18.86% Market Cap is $2.99 Mil as of Jun. 25, 2026. The stock has 4 warning signs investors should review. Among 1,431 Biotechnology companies, Iterum Therapeutics ranks worse than 95.04% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Iterum Therapeutics's share price for the quarter that ended in Sep. 2025 was $0.67. Iterum Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2025 was 48.99 Mil. Therefore, Iterum Therapeutics's market cap for the quarter that ended in Sep. 2025 was $32.82 Mil.
Iterum Therapeutics's quarterly market cap
declined
from Mar. 2025 ($43.90 Mil) to Jun. 2025 ($41.92 Mil) and
declined
from Jun. 2025 ($41.92 Mil) to Sep. 2025 ($32.82 Mil).
Iterum Therapeutics's annual market cap
increased
from Dec. 2022 ($10.58 Mil) to Dec. 2023 ($26.59 Mil) and
increased
from Dec. 2023 ($26.59 Mil) to Dec. 2024 ($55.82 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Iterum Therapeutics's Enterprise Value for Today is $25.72 Mil.
Iterum Therapeutics (OTCPK:ITRMF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Iterum Therapeutics Market Cap Related Terms
Iterum Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Iterum Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Iterum Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iterum Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Iterum Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Iterum Therapeutics's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iterum Therapeutics (ITRMF) has a Market Cap of $2.99 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Iterum Therapeutics and its competitors. According to the industry distribution chart, Iterum Therapeutics ranks #1360 out of 1431 companies in the Biotechnology industry, placing it in the top 95%.
Is Iterum Therapeutics' Market Cap too high?
Iterum Therapeutics' current Market Cap is $2.99 Mil. The Biotechnology industry median Market Cap is 117.63. Iterum Therapeutics' value of $2.99 Mil is 97.5% below this industry median. Based on the distribution chart, Iterum Therapeutics ranks #1360 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Iterum Therapeutics' Market Cap compare to ENSC and PPCB?
According to the Biotechnology industry distribution chart, Iterum Therapeutics ranks #1360 out of 1431 companies for Market Cap. This places Iterum Therapeutics in the lower half of its industry. The industry median Market Cap is 117.63. Iterum Therapeutics' value of $2.99 Mil is 97.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iterum Therapeutics's current Market Cap of $2.99 Mil is 97.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Iterum Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iterum Therapeutics's current Market Cap is $2.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current Market Cap of $2.99 Mil. The current Market Cap is $2.99 Mil and 97.5% below the Biotechnology industry median of 117.63. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current Market Cap is $2.99 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITRMF has been successfully added to your 